Savara Inc.
SVRA Real Time Price USDRecent trades of SVRA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SVRA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Dry powder vancomycin compositions and associated methods Feb. 18, 2020
-
Patent Title: Formulations of aminoglycoside and fosfomycin in combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis Nov. 12, 2019
-
Patent Title: Dry powder vancomycin compositions and associated methods Sep. 24, 2019
-
Patent Title: Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Sep. 10, 2019
-
Patent Title: Dry powder vancomycin compositions and associated methods Feb. 21, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SVRA in WallStreetBets Daily Discussion
Recent insights relating to SVRA
Recent picks made for SVRA stock on CNBC
ETFs with the largest estimated holdings in SVRA
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SVRA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.